Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
2012 (English)In: Cancer Cell, ISSN 1535-6108, E-ISSN 1878-3686, Vol. 21, no 1, 82-91 p.Article in journal (Refereed) Published
Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([11C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [11C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.
Place, publisher, year, edition, pages
2012. Vol. 21, no 1, 82-91 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-168585DOI: 10.1016/j.ccr.2011.11.023ISI: 000299365000010OAI: oai:DiVA.org:uu-168585DiVA: diva2:501554